 The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival PFS and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine DTIC or Temozolomide TMZ. 